Abstract
161Tb has many attractive properties (half‐life of 6.9 d, β−decay energy of 593 keV, conversion and Auger electron emission) for targeted radionuclide therapy with peptides and antibodies.1 161Tb can be produced via neutron irradiation of 160Gd in a nuclear reactor, such as BR2(flux of circa 1014 neutrons cm−2 s−1) at SCK•CEN. The aim of this project was to develop a fast and easy method
to purify small amounts (circa 250 MBq) of n.c.a. 161Tb with high specific activity, for radiolabeling studies and in‐house chelator design
to purify small amounts (circa 250 MBq) of n.c.a. 161Tb with high specific activity, for radiolabeling studies and in‐house chelator design
Original language | English |
---|---|
Title of host publication | Supplement: The 23rd International Symposium on Radiopharmaceutical Sciences (ISRS 2019) Beijing, China, 26–31 May 2019 |
Pages | S303-S303 |
Number of pages | 1 |
Volume | 62 |
DOIs | |
State | Published - 24 May 2019 |
Event | ISRS 2019 - SRS Office, Beijing Duration: 26 May 2019 → 31 May 2019 https://www.srsweb.org/isrs2019 |
Publication series
Name | Journal of Labelled Compounds and Radiopharmaceuticals |
---|---|
Publisher | Wiley - John Wiley & Sons, Ltd |
ISSN (Print) | 0362-4803 |
Conference
Conference | ISRS 2019 |
---|---|
Country/Territory | China |
City | Beijing |
Period | 2019-05-26 → 2019-05-31 |
Internet address |